Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

NCT06150742 · View on ClinicalTrials.gov ↗

Study Summary

A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.

Conditions Studied

Interventions

  • DEVICE Niyad (nafamostat mesylate)
  • DEVICE Placebo (0.9% NaCl)

Study Locations (10)

New York

  • Northwell Health — Great Neck
  • Mount Sinai — New York

California

  • University of California Los Angeles — Los Angeles

Florida

  • AdventHealth — Orlando

Michigan

  • Henry Ford Health — Detroit

New Mexico

  • University of New Mexico — Albuquerque

Ohio

  • Cincinnati Children's Hospital Medical Center — Cincinnati

Pennsylvania

  • University of Pittsburgh Medical Center — Pittsburgh

South Carolina

  • Medical University of South Carolina — Charleston

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-08-15
Est. Completion 2025-12
Phase NA

Sponsor

Talphera

8 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06150742

The ClinicalTrials.gov registry entry for NCT06150742 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions — of which Niyad (nafamostat mesylate) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06150742 reports 10 study locations spanning 9 distinct geographic areas — top geographies include New York, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06150742 about?

NCT06150742 is a clinical study titled "Nafamostat Efficacy in Phase 3 Registrational CRRT Study". A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleed...

What is the current status of trial NCT06150742?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-08-15. Estimated completion is 2025-12.

What conditions does trial NCT06150742 study?

This clinical trial studies the following conditions: Acute Kidney Injury. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06150742?

The interventions under investigation include: Niyad (nafamostat mesylate) (DEVICE), Placebo (0.9% NaCl) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06150742?

This trial is sponsored by Talphera, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06150742 being conducted?

This trial has 10 study locations across California, Florida, Michigan, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial